Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you help us understand the impact of insurance resets and deductibles on Q1 sales and whether it affects gross net or filled prescriptions? A: Mark Hahn, Chief Financial Officer: The main impact would be on commercial co-pay assistance due to high deductibles, but since commercial patients are a small portion, it won't significantly affect gross to net in Q1. Christopher Martin, Chief Commercial Officer: The momentum of the launch should outweigh any deductible resets, and we expect increasing new patients and refills despite these resets.
Q: How do you feel about the 2025 consensus of $254 million, and is it possible to break even this year? A: Mark Hahn, Chief Financial Officer: We could reach cash flow break-even at a quarterly run rate closer to $300 million annually. David Zaccardelli, CEO: While we don't comment directly on consensus, the trajectory is increasing, and we're confident in the uptake of Ohtuvayre.
Q: What are some potential headwinds for Ohtuvayre, and what is the market opportunity in Europe? A: David Zaccardelli, CEO: We don't see specific headwinds from competition or market dynamics. The unmet need in COPD is significant. In Europe, we're advancing regulatory processes but not starting operations. Our strategy involves partnering, and we'll gain clarity on this in 2025.
Q: How should we think about the average duration of therapy for Ohtuvayre, and is there upside to the six-month average duration assumption? A: David Zaccardelli, CEO: We use six refills per year as a benchmark, but early refill data suggests potential upside. It's early to characterize fully, but we're encouraged by the persistency and refill data.
Q: Are there any common themes among the 45% of HCPs not prescribing Ohtuvayre, and how significant is the nebulizer in peak sales? A: Christopher Martin, Chief Commercial Officer: The non-prescribers are typical late adopters. Market research shows all doctors see Ohtuvayre's benefits. The nebulizer is not a barrier; innovation trumps route of administration, and patients find it comforting.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.